Gilead Sciences Statistics
Total Valuation
Gilead Sciences has a market cap or net worth of $211.70 billion. The enterprise value is $229.98 billion.
| Market Cap | 211.70B |
| Enterprise Value | 229.98B |
Important Dates
The last earnings date was Thursday, October 29, 2026, after market close.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | Dec 15, 2026 |
Share Statistics
Gilead Sciences has 1.24 billion shares outstanding. The number of shares has decreased by -1.59% in one year.
| Current Share Class | 1.24B |
| Shares Outstanding | 1.24B |
| Shares Change (YoY) | -1.59% |
| Shares Change (QoQ) | +0.64% |
| Owned by Insiders (%) | 0.09% |
| Owned by Institutions (%) | 90.75% |
| Float | 1.24B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 20.84 |
| PS Ratio | 6.83 |
| Forward PS | 6.49 |
| PB Ratio | 16.24 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.36 |
| P/OCF Ratio | 14.62 |
| PEG Ratio | 2.81 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.69, with an EV/FCF ratio of 16.69.
| EV / Earnings | n/a |
| EV / Sales | 7.42 |
| EV / EBITDA | 15.69 |
| EV / EBIT | 19.41 |
| EV / FCF | 16.69 |
Financial Position
The company has a current ratio of 1.38, with a Debt / Equity ratio of 2.02.
| Current Ratio | 1.38 |
| Quick Ratio | 1.08 |
| Debt / Equity | 2.02 |
| Debt / EBITDA | 1.77 |
| Debt / FCF | 1.90 |
| Interest Coverage | 11.72 |
Financial Efficiency
Return on equity (ROE) is -22.45% and return on invested capital (ROIC) is 36.82%.
| Return on Equity (ROE) | -22.45% |
| Return on Assets (ROA) | 13.47% |
| Return on Invested Capital (ROIC) | 36.82% |
| Return on Capital Employed (ROCE) | 30.06% |
| Weighted Average Cost of Capital (WACC) | 5.74% |
| Revenue Per Employee | $1.82M |
| Profits Per Employee | -$227,176 |
| Employee Count | 17,000 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 3.38 |
Taxes
In the past 12 months, Gilead Sciences has paid $1.33 billion in taxes.
| Income Tax | 1.33B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +44.03% in the last 52 weeks. The beta is 0.33, so Gilead Sciences's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | +44.03% |
| 50-Day Moving Average | 150.87 |
| 200-Day Moving Average | 139.88 |
| Relative Strength Index (RSI) | 74.28 |
| Average Volume (20 Days) | 6,269,738 |
Short Selling Information
The latest short interest is 20.27 million, so 1.63% of the outstanding shares have been sold short.
| Short Interest | 20.27M |
| Short Previous Month | 21.83M |
| Short % of Shares Out | 1.63% |
| Short % of Float | 1.64% |
| Short Ratio (days to cover) | 3.40 |
Income Statement
In the last 12 months, Gilead Sciences had revenue of $30.99 billion and -$3.86 billion in losses. Loss per share was -$3.12.
| Revenue | 30.99B |
| Gross Profit | 24.77B |
| Operating Income | 11.85B |
| Pretax Income | -2.53B |
| Net Income | -3.86B |
| EBITDA | 14.66B |
| EBIT | 11.85B |
| Loss Per Share | -$3.12 |
Balance Sheet
The company has $7.95 billion in cash and $26.23 billion in debt, with a net cash position of -$18.28 billion or -$14.74 per share.
| Cash & Cash Equivalents | 7.95B |
| Total Debt | 26.23B |
| Net Cash | -18.28B |
| Net Cash Per Share | -$14.74 |
| Equity (Book Value) | 12.96B |
| Book Value Per Share | 10.51 |
| Working Capital | 4.55B |
Cash Flow
In the last 12 months, operating cash flow was $14.48 billion and capital expenditures -$699.00 million, giving a free cash flow of $13.78 billion.
| Operating Cash Flow | 14.48B |
| Capital Expenditures | -699.00M |
| Depreciation & Amortization | 2.81B |
| Net Borrowing | 1.28B |
| Free Cash Flow | 13.78B |
| FCF Per Share | $11.11 |
Margins
Gross margin is 79.95%, with operating and profit margins of 38.23% and -12.46%.
| Gross Margin | 79.95% |
| Operating Margin | 38.23% |
| Pretax Margin | -8.17% |
| Profit Margin | -12.46% |
| EBITDA Margin | 47.31% |
| EBIT Margin | 38.23% |
| FCF Margin | 44.47% |
Dividends & Yields
This stock pays an annual dividend of $3.28, which amounts to a dividend yield of 1.92%.
| Dividend Per Share | $3.28 |
| Dividend Yield | 1.92% |
| Dividend Growth (YoY) | 3.80% |
| Years of Dividend Growth | 10 |
| Payout Ratio | n/a |
| FCF Payout Ratio | 29.52% |
| Buyback Yield | 1.59% |
| Shareholder Yield | 3.51% |
| Earnings Yield | -1.83% |
| FCF Yield | 6.51% |
Analyst Forecast
The average price target for Gilead Sciences is $173.56, which is 1.69% higher than the current price. The consensus rating is "Buy".
| Price Target | $173.56 |
| Price Target Difference | 1.69% |
| Analyst Consensus | Buy |
| Analyst Count | 27 |
| Revenue Growth Forecast (3Y) | 5.85% |
| EPS Growth Forecast (3Y) | 10.21% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 28, 2013. It was a forward split with a ratio of 2:1.
| Last Split Date | Jan 28, 2013 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Gilead Sciences has an Altman Z-Score of 4.14 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.14 |
| Piotroski F-Score | 5 |